Role of poly(ADP-ribose) polymerase in cisplatin-induced injury in LLC-PK1 cells

Free Radical Biology and Medicine

Volumn 35, Issue 8, 2003, Pages 966-977

  Shino, Yuki ^a   Itoh, Yoshinori ^a   Kubota, Toshio ^a   Yano, Takahisa ^a   Sendo, Toshiaki ^a   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

ATP; Cisplatin; Free radicals; Hydroxyl radical; LLC PK1; Necrosis; Poly(ADP ribose) polymerase

Indexed keywords

3 AMINOBENZAMIDE; ADENOSINE TRIPHOSPHATE; BENZAMIDE; CISPLATIN; DIMETHYLTHIOUREA; HYDROXYL RADICAL; MANNITOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NORPHENAZONE;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVATION; KIDNEY TUBULE CELL; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SWINE;

LETHRINIDAE; SUIDAE;

EID: 0141637481     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(03)00470-2     Document Type: Article

References (46)

1. Leonard B.J., Eccleston E., Jones D., Todd P., Walpole A. Antileukaemic and nephtotoxic properties of platinum compounds. Nature. 234:1971;43-45.
2. Weiner M.W., Jacobs C. Mechanism of cisplatin nephrotoxicity. Fed. Proc. 42:1983;2974-2978.
3. Kuhlmann M.K., Burkhardt G., Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol. Dial. Transplant. 12:1997;2478-2480.
4. Anand A.J., Bashey B. Newer insights into cisplatin nephrotoxicity. Ann. Pharmacother. 27:1993;1519-1525.
5. Husain K., Morris C., Whitworth C., Trammell G.L., Rybak L.P., Somani S.M. Protection by ebselen against cisplatin-induced nephrotoxicity antioxidant system . Mol. Cell. Biochem. 178:1998;127-133.
6. Liu H., Baliga R. Effect of iron chelator, hydroxyl radical scavenger and cytochrome P450 inhibitors on the cytotoxicity of cisplatin to tumor cells. Anticancer Res. 20:2000;4547-4550.
7. Matsushima H., Yonemura K., Ohishi K., Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J. Lab. Clin. Med. 131:1998;518-526.
8. Yuhas J.M., Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat. Rep. 64:1980;57-64.
9. Sueishi K., Mishima K., Makino K., Itoh Y., Tsuruya K., Hirakata H., Oishi R. Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats. Eur. J. Pharmacol. 451:2002;203-208.
10. Racz I., Tory K., Gallyas F. Jr., Berente Z., Osz E., Jaszlits L., Bernath S., Sumegi B., Rabloczky G., Literati-Nagy P. BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol. 63:2002;1099-1111.
11. Bürkle A., Chen G., Kupper J.H., Grube K., Zeller W.J. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis. 14:1993;559-561.
12. Lieberthal W., Triaca V., Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells apoptosis vs. necrosis . Am. J. Physiol. 270:1996;F700-F708.
13. Lau A.H. Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int. 56:1999;1295-1298.
14. Cummings B.S., Schnellmann R.G. Cisplatin-induced renal cell apoptosis caspase 3-dependent and -independent pathways . J. Pharmacol. Exp. Ther. 302:2002;8-17.
15. Park M.S., De Leon M., Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J. Am. Soc. Nephrol. 13:2002;858-865.
16. Bai Y., Suzuki A.K., Sagai M. The cytotoxic effects of diesel exhaust particles on human pulmonary artery endothelial cells in vitro role of active oxygen species . Free Radic. Biol. Med. 30:2001;555-562.
17. Kawamitsu H., Hoshino H., Okada H., Miwa M., Momoi H., Sugimura T. Monoclonal antibodies to poly(adenosine diphosphate ribose) recognize different structures. Biochemistry. 23:1984;3771-3777.
18. Floyd R.A., Henderson R., Watson J.J., Wong P.K. Use of salicylate with high pressure liquid chromatography and electrochemical detection (LCED) as a sensitive measure of hydroxyl free radicals in adriamycin treated rats. Free Radic. Biol. Med. 2:1986;13-18.
19. Sasaki H., Okabe E. Modification by hydroxyradicals of functional reactivity in rabbit lingual artery. Jpn. J. Pharmacol. 62:1993;305-314.
20. Oka M., Hirouchi M., Itoh Y., Ukai Y. Involvement of peroxynitrite and hydroxyradical generated from nitric oxide in hypoxia/reoxygenation injury in rat cerebrocortical slices. Neuropharmacology. 39:2000;1319-1330.
21. Zhang J., Piantadosi C.A. Prolonged production of hydroxyl radical in rat hippocampus after brain ischemia-reperfusion is decreased by 21-aminosteroids. Neurosci. Lett. 177:1994;127-130.
22. 2+ channel blocker NS-7 of severe to mild hypoxic injury in rat cerebrocortical slices a possible involvement of a highly voltage-dependent blockade of Ca(2+) channel . J. Pharmacol. Exp. Ther. 293:2000;522-529.
23. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
24. Martin D.S., Schwartz G.K. Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Oncol. Res. 9:1997;1-5.
25. Ha H.C., Snyder S.H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc. Natl. Acad. Sci. USA. 96:1999;13978-13982.
26. van Heerde W.L., Robert-Offerman S., Dumont E., Hofstra L., Doevendans P.A., Smits J.F., Daemen M.J., Reutelingsperger C.P. Markers of apoptosis in cardiovascular tissues focus on Annexin V . Cardiovasc. Res. 45:2000;549-559.
27. Fadok V.A., Voelker D.R., Campbell P.A., Cohen J.J., Bratton D.L., Henson P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148:1992;2207-2216.
28. Thomas L.B., Gates D.J., Richfield E.K., O'Brien T.F., Schweitzer J.B., Steindler D.A. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp. Neurol. 133:1995;265-272.
29. Tornusciolo D.R., Schmidt R.E., Roth K.A. Simultaneous detection of TDT-mediated dUTP-biotin nick end-labeling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections. Biotechniques. 19:1995;800-805.
30. Dobyan D.C., Levi J., Jacobs C., Kosek J., Weiner M.W. Mechanism of cis-platinum nephrotoxicity II. Morphologic observations . J. Pharmacol. Exp. Ther. 213:1980;551-556.
31. Bompart G. Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug-metabolizing enzyme activities in rat kidney cortex. Toxicol. Lett. 48:1989;193-199.
32. Alfieri A.B., Cubeddu L.X. Role of NK1 receptors on cisplatin-induced nephrotoxicity in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 361:2000;334-338.
33. Saad S.Y., Al-Rikabi A.C. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy. 48:2002;42-48.
34. Gonzales-Vitale J.C., Hayes D.M., Cvitkovic E., Sternberg S.S. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 39:1977;1362-1371.
35. Okuda M., Masaki K., Fukatsu S., Hashimoto Y., Inui K. Role of apoptosis in cisplatin-induced toxicity in the renal epithelial cell line LLC-PK1. Implication of the functions of apical membranes. Biochem. Pharmacol. 59:2000;195-201.
36. Gemba M., Yamaguchi T., Kambara K., Suzuki A., Kawai Y. Increases in urinary enzyme excretion in rats depleted of glutathione inhibited by scavenger of oxygen free radicals. J. Pharmacobiodyn. 15:1992;513-518.
37. Kim Y.K., Jung J.S., Lee S.H., Kim Y.W. Effects of antioxidants and Ca2+ in cisplatin-induced cell injury in rabbit renal cortical slices. Toxicol. Appl. Pharmacol. 146:1997;261-269.
38. Baliga R., Zhang Z., Baliga M., Ueda N., Shah S.V. Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney Int. 54:1998;1562-1569.
39. Weichert-Jacobsen K.J., Bannowski A., Kuppers F., Loch T., Stockle M. Direct amifostine effect on renal tubule cells in rats. Cancer Res. 59:1999;3451-3453.
40. Kemp G., Rose P., Lurain J., Berman M., Manetta A., Roullet B., Homesley H., Belpomme D., Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities results of a randomized control trial in patients with advanced ovarian cancer . J. Clin. Oncol. 14:1996;2101-2112.
41. Culy C.R., Spencer C.M. Amifostine an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome . Drugs. 61:2001;641-684.
42. Kruidering M., Van de Water B., de Heer E., Mulder G.J., Nagelkerke J.F. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain . J. Pharmacol. Exp. Ther. 280:1997;638-649.
43. Chatterjee S., Berger S.J., Berger N.A. Poly(ADP-ribose) polymerase a guardian of the genome that facilitates DNA repair by protecting against DNA recombination . Mol. Cell. Biochem. 193:1999;23-30.
44. Jung J.S., Park M.Y., Lee R.H., Jun J.S., Kim Y.K. Protection against hydrogen peroxide induced injury in renal proximal tubule cell lines by inhibition of poly(ADP-ribose) synthase. Kidney Blood Press. Res. 23:2000;14-19.
45. Min S.K., Kim S.Y., Kim C.H., Woo J.S., Jung J.S., Kim Y.K. Role of lipid peroxidation and poly(ADP-ribose) polymerase activation in oxidant-induced membrane transport dysfunction in opossum kidney cells. Toxicol. Appl. Pharmacol. 166:2000;196-202.
46. Filipovic D.M., Meng X., Reeves W.B. Inhibition of PARP prevents oxidant-induced necrosis but not apoptosis in LLC-PK1 cells. Am. J. Physiol. 277:1999;F428-F436.